Latest News Releases Keyword Search Year None20242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996 4/10/24 Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results 4/3/24 Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder 3/28/24 Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults 3/11/24 Neurocrine Biosciences to Participate at Virtual Investor Conferences in March 2/27/24 Neurocrine Biosciences to Participate at Investor Conferences in March 2/7/24 Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 1/17/24 Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results 1/2/24 Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference